Knockdown of PIMREG modulates the Wnt/β-catenin pathway to suppress proliferation and stemness in endometrial cancer

Background: Endometrial cancer is the most common gynecological malignancy, and poses serious threat to health. PIMREG (PICALM interacting mitotic regulator also known as FAM64A), has been uncovered in promoting tumorigenesis in multiple cancers. But, its regulatory impacts in endometrial cancer remain poorly understood. Methods: Cell viability was assessed by the Cell Counting Kit-8 (CCK-8) assay. Protein levels were inspected by Western blotting. Cell proliferation was evaluated by colony formation assay, while stemness was examined by sphere formation assays. Results: PIMREG expression was found to be upregulated in endometrial cancer. Suppression of PIMREG significantly reduced cell viability and suppressed proliferative and stemness capacities. Furthermore, silencing PIMREG retarded the evoking of the Wnt/β-catenin signaling pathway. Conclusions: PIMREG knockdown suppressed proliferation and stemness by modulating the Wnt/β-catenin pathway in endometrial cancer. This project hinted that PIMREG may be one useful therapeutic target for endometrial cancer treatment.

PIMREG; Wnt/β-catenin pathway; Endometrial cancer; Stemness

[1] Baker-Rand H, Kitson SJ. Recent advances in endometrial cancer prevention, early diagnosis and treatment. Cancers. 2024; 16: 1028.

[2] Galant N, Krawczyk P, Monist M, Obara A, Gajek Ł, Grenda A, et al. Molecular classification of endometrial cancer and its impact on therapy selection. International Journal of Molecular Sciences. 2024; 25: 5893.

[3] Matoba Y, Devins KM, Milane L, Manning WB, Mazina V, Yeku OO, et al. High-grade endometrial cancer: molecular subtypes, current challenges, and treatment options. Reproductive Sciences. 2024; 31: 2541–2559.

[4] Cai Y, Wang B, Xu W, Liu K, Gao Y, Guo C, et al. Endometrial cancer: genetic, metabolic characteristics, therapeutic strategies and nanomedicine. Current Medicinal Chemistry. 2021; 28: 8755–8781.

[5] Garrett AA, Bai S, Cascio S, Gupta N, Yang D, Buckanovich RJ. EGFL6 promotes endometrial cancer cell migration and proliferation. Gynecologic Oncology. 2024; 185: 75–82.

[6] Yang X, Liu Z, Tang W, Pratap UP, Collier AB, Altwegg KA, et al. PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis. Molecular Oncology. 2024; 18: 2136–2156.

[7] Zhang C, Zhang H, Yang X, Li S, Wang L, Su H, et al. MYO3B promotes cancer progression in endometrial cancer by mediating the calcium ion–RhoA/ROCK1 signaling pathway. Journal of Cancer Research and Clinical Oncology. 2024; 150: 424.

[8] Li C, Zhu D, Cao X, Li Y, Hao X. Knockdown of S100A2 inhibits the aggressiveness of endometrial cancer by activating STING pathway. Journal of Obstetrics and Gynaecology. 2024; 44: 2361849.

[9] Archangelo LF, Greif PA, Hölzel M, Harasim T, Kremmer E, Przemeck GKH, et al. The CALM and CALM/AF10 interactor CATS is a marker for proliferation. Molecular Oncology. 2008; 2: 356–367.

[10] Jiang L, Ren L, Zhang X, Chen H, Chen X, Lin C, et al. Overexpression of PIMREG promotes breast cancer aggressiveness via constitutive activation of NF-κB signaling. EBioMedicine. 2019; 43: 188–200.

[11] Serafim RB, Cardoso C, Arfelli VC, Valente V, Archangelo LF. PIMREG expression level predicts glioblastoma patient survival and affects temozolomide resistance and DNA damage response. Biochimica et Biophysica Acta. Molecular Basis of Disease. 2022; 1868: 166382.

[12] Jiang F, Liang M, Huang X, Shi W, Wang Y. High expression of PIMREG predicts poor survival outcomes and is correlated with immune infiltrates in lung adenocarcinoma. PeerJ. 2021; 9: e11697.

[13] Zhu H, Hu X, Ye Y, Jian Z, Zhong Y, Gu L, et al. Pan-cancer analysis of PIMREG as a biomarker for the prognostic and immunological role. Frontiers in Genetics. 2021; 12: 687778.

[14] Zhang J, Qian L, Wu J, Lu D, Yuan H, Li W, et al. Up-regulation of FAM64A promotes epithelial-to-mesenchymal transition and enhances stemness features in breast cancer cells. Biochemical and Biophysical Research Communications. 2019; 513: 472–478.

[15] Liu Y, Wang H. Biomarkers and targeted therapy for cancer stem cells. Trends in Pharmacological Sciences. 2024; 45: 56–66.

[16] Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduction and Targeted Therapy. 2024; 9: 170.

[17] Yin W, Wang J, Jiang L, James Kang Y. Cancer and stem cells. Experimental Biology and Medicine. 2021; 246: 1791–1801.

[18] Chu Y, Jin X, Guo X. MCM2 promotes the stemness of endometrial cancer cells via the Akt/β-catenin pathway. Neoplasma. 2023; 70: 610–620.

[19] Gong K, Zheng Y, Liu Y, Zhang T, Song Y, Chen W, et al. Phosphocholine inhibits proliferation and reduces stemness of endometrial cancer cells by downregulating mTOR-c-Myc signaling. Cellular and Molecular Life Sciences. 2024; 82: 3.

[20] Li Y, Liu Q, McGrail DJ, Dai H, Li K, Lin SY. CHD4 mutations promote endometrial cancer stemness by activating TGF-beta signaling. American Journal of Cancer Research. 2018; 8: 903–914.

[21] Zhao N, Guo Y, Liu P, Chen Y, Wang Y. Sirtuin 2 promotes cell stemness and MEK/ERK signaling pathway while reduces chemosensitivity in endometrial cancer. Archives of Gynecology and Obstetrics. 2022; 305: 693–701.

[22] Zhao X, Ma Y, Luo J, Xu K, Tian P, Lu C, et al. Blocking the WNT/β-catenin pathway in cancer treatment:pharmacological targets and drug therapeutic potential. Heliyon. 2024; 10: e35989.

[23] Wang WL, Hong GC, Chien PJ, Huang YH, Lee HT, Wang PH, et al. Tribbles pseudokinase 3 contributes to cancer stemness of endometrial cancer cells by regulating β-catenin expression. Cancers. 2020; 12: 3785.

[24] Zhang W, Ruan X, Li Y, Zhi J, Hu L, Hou X, et al. KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway. Theranostics. 2022; 12: 1500–1517.

[25] Liu X, Su K, Sun X, Jiang Y, Wang L, Hu C, et al. Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/β-catenin pathway. Journal of Experimental & Clinical Cancer Research. 2021; 40: 32.

[26] Zhang X, Zhang R, Hou C, He R, Wang Q, Zhou T, et al. FOXF2 oppositely regulates stemness in luminal and basal-like breast cancer cells through the Wnt/beta-catenin pathway. Journal of Biological Chemistry. 2022; 298: 102082.

[27] Huang J, Sun X, Diao G, Li R, Guo J, Han J. KIF15 knockdown inhibits the development of endometrial cancer by suppressing epithelial-mesenchymal transition and stemness through Wnt/β-catenin signaling. Environmental Toxicology. 2023; 38: 1824–1834.

[28] Wang D, Hu A, Peng H, Li D, Zhang L. Tumor-promoting function of PIMREG in glioma by activating the β-catenin pathway. 3 Biotech. 2021; 11: 380.